Clinical Trials on Unresectable Stage III Non-small-cell Lung Cancer

Total 7707 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

Recurrent Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 and other conditions

United States
Washington University School of Medicine

Completed

A Phase I/II Trial of Stereotactic Body Radiation Therapy (SBRT)

Inoperable Stage I/II Non-small Cell Lung Cancer

United States
MedImmune LLC

Completed

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

NSCLC | Resectable | Early-stage

United States, Canada, Switzerland, Italy, France, Portugal, Spain
Shanghai Chest Hospital
Fudan University; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaborators

Unknown

To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

Radiotherapy | Non-small Cell Lung Cancer Stage IIIA

China
AstraZeneca

Completed

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. (SELECT-2)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Poland, France, Germany, Brazil, Hungary, Netherlands, Bulgaria
AstraZeneca
Quintiles, Inc.

Completed

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

United States
Washington University School of Medicine
Merck Sharp & Dohme LLC

Withdrawn

Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Small Cell Lung Extensive Stage
University Hospital, Essen
German Cancer Aid

Not yet recruiting

Exercise in Patients With Advanced Non-small Cell Lung Cancer (BREATH)

Advanced Lung Carcinoma | NSCLC Stage IV | NSCLC Stage IIIB | First Line Treatment | Second Line Treatment | Palliative Treatment | NSCLC Stage IIIC

Germany
Shanghai Chest Hospital

Unknown

To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

Radiotherapy | Non-small Cell Lung Cancer Stage IIIA

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy

Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Active, not recruiting

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer | Malignant Pleural Effusion | Adenosquamous Cell Lung Cancer

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Terminated

Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Malignant Pleural Effusion | Malignant Pericardial Effusion

United States
National Cancer Institute (NCI)

Withdrawn

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Lung Non-Small Cell Carcinoma | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Superior Sulcus Lung Carcinoma

United States
University Hospital Heidelberg
Roche Pharma AG

Recruiting

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC (iReP)

NSCLC Stage IIIB | NSCLC Stage II | NSCLC, Stage IIIA

Germany
Roswell Park Cancer Institute

Completed

Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis

Stage IIIB Non-Small Cell Lung Cancer | Stage IV Non-Small Cell Lung Cancer | Stage IV Adult Soft Tissue Sarcoma | Metastatic Malignant Neoplasm in the Lung

United States
Emory University
National Cancer Institute (NCI)

Withdrawn

Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8
AstraZeneca

Active, not recruiting

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Canada, France, Italy, Spain, United Kingdom, Belgium, Poland, Brazil, Germany, Hungary, Peru, Russian Federation, Turkey, Australia, Chile, Austria, Netherlands, Portugal, Israel, Mexico, Romania, Sweden, Ukraine, Bulgaria, Argenti...
OncoHost Ltd.

Recruiting

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments (PROPHETIC)

Stage IV Non-small Cell Lung Cancer | Stage III Malignant Melanoma | Stage IV Small Cell Lung Cancer | Stage IV Malignant Melanoma

United States, Israel, United Kingdom, Germany, Spain
iTeos Belgium SA

Recruiting

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Metastatic NSCLC | Stage III NSCLC

United States, Belgium, Spain, Switzerland, Italy, France, Canada, Poland, Czechia
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Lung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom
AstraZeneca

Completed

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced, NSCLC

Unresectable Non-small Cell Lung Cancer (NSCLC) and Urothelial Cancer

India
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Sarcoma | Glioblastoma | Recurrent Ovarian Carcinoma | Recurrent Uterine Corpus Carcinoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Metastatic Renal Cell Cancer | Recurrent Lung Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Non Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Non Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
University of Pennsylvania

Terminated

Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Starting Pemetrexed Based Therapy | Unresectable Cancer

United States
Thomas Jefferson University
National Cancer Institute (NCI)

Completed

Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer... and other conditions

United States
Guangdong Provincial People's Hospital

Recruiting

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Surgery | Stage III NSCLC

China
Maximilian Diehn
AstraZeneca

Recruiting

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Non Small Cell Lung Cancer | NSCLC, Stage III | Nsclc

United States
Odense University Hospital

Not yet recruiting

Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC (HERAN2)

Frailty | Non-small Cell Lung Cancer Stage III | Radiotherapy Side Effect
Radiotherapy Oncology Centre "Santa Maria" Hospital
Paola Anselmo,MD; Michelina Casale,PhD; Fabio Trippa,MD

Recruiting

Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer (STARTNEWERA-OM)

NSCLC | Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Oligometastatic Disease | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Non-Small Cell Adenocarcinoma and other conditions

Italy
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate Cancer

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate... and other conditions

United States
University of British Columbia
AstraZeneca; Ozmosis Research Inc.

Recruiting

SCION: SABR and Checkpoint Inhibition Of NSCLC (SCION)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Lung Cancer Stage I | Lung Adenocarcinoma, Stage I | Lung Squamous Cell Carcinoma Stage I

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer

Anal Squamous Cell Carcinoma | Stage III Anal Cancer AJCC v8 | Stage IIB Anal Cancer AJCC v8 | Stage IIIA Anal Cancer AJCC v8 | Stage IIIB Anal Cancer AJCC v8 | Stage IIIC Anal Cancer AJCC v8 | Stage I Anal Cancer AJCC v8 | Stage II Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8 | Stage 0 Anal Cancer...

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes

Stage IV Prostate Cancer AJCC v8 | Hepatobiliary Neoplasm | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Malignant Neoplasm and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Gallbladder Cancer AJCC v8 | Stage IIIA Gallbladder Cancer AJCC v8 | Stage IIIB Gallbladder Cancer AJCC v8 | Unresectable Extrahepatic... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Northwestern University
National Cancer Institute (NCI); Varian Medical Systems

Recruiting

Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study

Lung Non-Small Cell Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Lung

United States
Jonsson Comprehensive Cancer Center
Eli Lilly and Company; Genentech, Inc.

Recruiting

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

NSCLC | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Non-small Cell Carcinoma

United States
University of Wisconsin, Madison
AstraZeneca

Terminated

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IV

United States
UNICANCER
National Cancer Institute, France

Recruiting

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG)

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Non-Small Cell Carcinoma of Lung, TNM Stage 4

France, Monaco
Yonsei University

Recruiting

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Potentially Resectable Stage II/IIIa NSCLC

Korea, Republic of
Albert Einstein College of Medicine
National Cancer Institute (NCI); Eli Lilly and Company; OSI Pharmaceuticals

Completed

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Bronchioloalveolar Carcinoma | Large Cell Lung Carcinoma

United States
Washington University School of Medicine
Varian Medical Systems

Recruiting

Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Early Stage Non-small Cell Lung Cancer

United States
University of Washington
National Cancer Institute (NCI); Syntrix Biosystems, Inc.

Recruiting

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
University of Rome Tor Vergata

Completed

Assessment of Ergonomics in 3D vs 2D Thoracoscopic Lobectomy

Early Stage Non-small-cell Lung Cancer (Stage 1-2)

Italy
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Recurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma (Locally Advanced) | Stage IIC Melanoma (Locally Advanced) | Stage IV Melanoma (Limited, Resectable)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial

Stage III Anal Cancer AJCC v8 | Anal Canal Squamous Cell Carcinoma | Stage IIB Anal Cancer AJCC v8 | Stage IIIA Anal Cancer AJCC v8 | Stage IIIB Anal Cancer AJCC v8 | Stage IIIC Anal Cancer AJCC v8 | Stage I Anal Cancer AJCC v8 | Stage II Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8

United States
Massachusetts General Hospital
American Lung Association

Recruiting

Patient-centered, Optimal Integration of Survivorship and Palliative Care

Carcinoma, Non-Small-Cell Lung | Nonsmall Cell Lung Cancer | Palliative Care | Survivorship | Targeted Therapy | Stage IV Non-small Cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer | ALK-positive Non-small Cell Lung Cancer

United States

Clinical Trials on Unresectable Stage III Non-small-cell Lung Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations